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Abstract 
The aryl hydrocarbon receptor (AHR) is a ligand-activated transcription factor that 
mediates a toxic response to many environmental contaminants. Cartilaginous fishes, due 
to gene duplication events, express 4 distinct AHR genes. Squalus acanthias AHR1 
(SaAHR1) does not bind to typical AHR agonists, including dioxin-like chemicals 
(DLCs), whereas SaAHR2 binds to DLCs and subsequently upregulates genes containing 
dioxin responsive elements. Three-dimensional homology models were created based 
upon both human HIF1α and human HIF2α structural templates. These models yielded 
different secondary structural characteristics, most notably in the length of the β-strand 
on the C-terminal end of the ligand binding domain, which is centrally located in the 
antiparallel β-sheet that makes up a large portion of the ligand binding cavity. Residue 
A375 is located in a possible hinge area on this β-strand, and the mutation A375C would 
change this alanine residue in the nonbinding SaAHR1 to its analog in the DLC-binding 
SaAHR2, which may increase SaAHR1’s binding affinity to DLCs. The SaAHR1 also 
has a novel diproline motif comprising residues 379 and 380, located on the same β-
strand as residue 375. This motif is not known to be found in any other AHR isoforms. 
Reversion of the diproline motif to proline-leucine, its analogous residues in SaAHR2, 
did not restore PCB 126 induced activation of a luciferase reporter gene. Epifluorescence 
microscopy using a heterologous expression system and an eGFP-SaAHR1 DNA 
construct revealed a nuclear localization unique to this isoform. Further characterization 
of this non-binding receptor could help to determine species-specific sensitivities to AHR 
agonists, especially in animals that are unavailable for direct experimentation (i.e.: 
endangered species). 
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1. Introduction 
Environmental chemical pollutants are ubiquitous. They are present in the air we 
breathe, the water we drink, and the food we eat. Some chemicals are transient and break 
down by photolysis or natural bioremediation, whereas others are incredibly stable and 
may not break down for decades. Unfortunately, a great deal of stable chemicals are 
hydrophobic and lipophilic, partitioning into the fat of an organism1. Furthermore, 
hydrophobic chemicals partition into plastics2, where they can pose a long-term exposure 
risk to the environment. These chemicals can accumulate in organisms and magnify 
exponentially up the food chain. This means that apex predators, including humans, will 
have high chemical body burdens relative to lower trophic levels3. 
Another characteristic of hydrophobic or lipophilic chemicals is that they easily 
pass through plasma membranes1. As such, these chemicals make their way into animal 
cells easily, where depending on their mechanism of action, they can affect the cell on a 
molecular level. This molecular change can cause damage in a multitude of ways such as 
altering gene transcription or blocking normal functions4. This dysbiosis can affect 
multiple downstream processes through molecular cascade effects, which ultimately 
magnify the overall effect. One such interface between chemicals and cellular effects is 
the receptor protein. 
1.1 Receptor proteins  
 Receptor proteins bind to specific chemicals and undergo changes in structural 
conformation, providing chemical signals for downstream processes4. A chemical that 
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binds to a receptor protein is known as a ligand. A ligand can either be an agonist, which 
is a chemical that binds and mediates a downstream response, or an antagonist, which is a 
chemical that binds and causes the receptor to be nonfunctional in its normal downstream 
response. A receptor’s affinity to bind a ligand is dependent on its biochemical 
properties, the functional domains it possesses, and the identity of key amino acid 
residues5.  
 Receptor proteins can be localized in different cellular compartments, and as such 
will have different functions such as initiating and transmitting a signal or acting as a 
transcription factor5. Membrane-bound receptors recognize chemical signals outside of 
the cell and upon binding undergo a conformational change, normally the first step in a 
chemical cascade. Cytoplasmic receptors, such as the aryl hydrocarbon receptor (AHR), 
are localized in the cytoplasm and have various functions upon activation, including gene 
regulation. Nuclear receptors, such as the estrogen receptor (ER), are usually involved in 
gene regulation due to their proximity to DNA6. Some nuclear receptors, such as the 
thyroid hormone receptor are constitutively bound to their hormone receptor elements 
(HREs) on DNA even when inactive and bind to their respective hormones directly 
adjacent to the gene they regulate6. 
1.2 Exogenous chemicals  
 Since the industrial revolution, humans have been polluting the environment with 
large volumes of chemical waste7. Chemical pollutants can originate from point sources, 
such as discharge pipe effluent from a manufacturing plant, or non-point sources, such as 
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pesticide or fertilizer runoff from farmland1. A recent uptick in extreme weather events, 
attributed to global climate change, may increase the amount of chemical runoff that 
leads into waterways and marine environments8. Exogenous, otherwise known as 
xenobiotic, chemicals can interact with wildlife, induce toxicity in organisms, and cause 
deleterious effects on the ecological communities exposed1. 
1.2.1 Persistent organic pollutants 
Many anthropogenic chemicals, including halogenated aromatic hydrocarbons 
(HAHs), are persistent organic pollutants (POPs), exhibiting high stabilities and low 
degradation rates1. These compounds persist in the environment, bioaccumulate in 
individuals, and biomagnify up food-web trophic levels. Bioaccumulation occurs on the 
organismal level, when an individual’s chemical uptake occurs faster than the chemical 
can be metabolized or excreted. Another key factor in bioaccumulation is the 
hydrophobic and lipophilic nature of many persistent chemicals, which causes 
partitioning into an individual’s fatty tissues, where any metabolism may be reduced. 
Biomagnification occurs at higher trophic levels when an individual consumes numerous 
animals of lower trophic levels, each of which have accumulated a chemical burden 
throughout their lifetime. Apex predators are at the highest risk of increased lipophilic 
chemical load due to both biomagnification and bioaccumulation1. 
1.2.2 Dioxins 
Dioxins are chemical byproducts of volcanos and other combustion events and 
have been present in the environment for billions of years1. Although dioxins are 
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produced from these natural sources, much more has been released into the environment 
from industrial processes9. A few examples of industrial dioxin sources include effluent 
waste from the manufacturing of some pesticides and herbicides, and processes such as 
smelting and bleaching of paper pulp9. A well-known dispersal of dioxins occurred 
during the Vietnam war as an unintended ingredient in the military defoliant known as 
Agent Orange10.  
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), one of the most potent and well-
studied dioxins, is of special interest to AHR chemistry because this co-planar molecule 
binds to most mammalian AHRs with the highest affinity of any known AHR agonist11. 
Because of this high affinity to AHRs, TCDD is often used as a model coplanar chemical 
to study the binding properties of AHR:agonist relationships. 
1.2.3 Polychlorinated biphenyls 
Polychlorinated biphenyls (PCBs) are a group of environmental pollutants that 
were used heavily in industry for their high stability1, which is ironically the same 
characteristic that makes these chemicals persist in the environment. These legacy 
chemicals, although banned by most countries, are still present in the environment in high 
concentrations, especially in sites where they were produced or dumped. One such 
contaminated site is New Bedford Harbor, Massachusetts, in which two electrical 
component plants used and improperly disposed of PCB-mixtures called Aroclors for 30 
years before production was outlawed in the United States in 197812. Remediation of this 
area is still ongoing, with approximately 485,000 cubic yards of sediment dredged and 
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disposed of as of September 201813. Some congeners of PCBs are co-planar chemicals 
and are considered dioxin-like compounds (DLCs) due to their structural similarities to 
TCDD14. These co-planar PCBs are of interest to researchers due to a high affinity to 
mammalian AHRs11. 
1.3 The aryl hydrocarbon receptor  
The aryl hydrocarbon receptor (AHR) is a cytosolic ligand-activated transcription 
factor in the basic-helix-loop-helix Per-ARNT-Sim (bHLH-PAS) family of 
environmental sensor proteins15. AHR binds with high affinity to a number of structurally 
related xenobiotic toxins, such as halogenated aromatic hydrocarbons (HAH) and 
polycyclic aromatic hydrocarbons (PAH), and mediates their toxic effects16. Potentially 
harmful AHR agonists have been found in many products consumers use daily, such as 
newspaper ink and rubber17. The AHR also binds to many nontoxic ligands, including 
endogenous chemicals such as tryptophan derivatives, and mediates normal physiological 
responses such as regulating immune function18. 
 The superfamily of basic-helix-loop-helix Per-ARNT-Sim (bHLH-PAS) 
environmental sensor transcription factors control expression of homeostatic genes. This 
protein family also includes but is not limited to hypoxia inducible factor (HIF), single 
minded protein (SIM), and circadian locomotor output cycles kaput (CLOCK)19. In each 
of these proteins, the bHLH domain interacts directly with enhancer sequences on target 
genes to control gene activation, whereas PAS domains usually control activation or 
ligand binding and a subsequent dimerization step necessary to create a transcription 
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factor complex19. These domains work in conjunction to provide bHLH-PAS 
transcription factors with signal-induced control over a subset of the cell’s transcriptional 
output. bHLH-PAS proteins exhibit sequence homology and as such are considered 
evolutionarily related19.  
1.3.1 AHR chaperones  
Prior to ligand binding, the AHR is complexed with the chaperone proteins AHR-
associated protein 9 (ARA9), heat shock protein 90 (HSP90), and the cochaperone 
prostaglandin E synthase 3 (PTGES3, also known as P23). A homodimer of HSP90, 
which is named due to its molecular weight of 90 kilodaltons (kDa), helps maintain an 
“open” conformation in the AHR ligand-binding cavity and blocks the DNA-binding 
domain (DBD), preventing premature DNA binding20. ARA9, also known as AHR-
interacting protein (AIP) and xenobiotic-associated protein 2 (XAP2), has a molecular 
weight of 37 kDa and is thought to protect the AHR complex from proteasomal 
degradation and control AHR’s cellular localization21. The cochaperone P23 is necessary 
for the ligand-dependent translocation of AHR, the dissociation of the HSP90 dimer, and 
protects the AHR from degradation22. 
1.3.2 AHR activation  
Once ligand binding occurs, the AHR translocates into the nucleus, where it 
dimerizes with its partner protein, the aryl hydrocarbon receptor nuclear translocator 
(ARNT) (Figure 1). The newly formed AHR:ARNT heterodimer acts as transcription 
factor, upregulating genes that contain a dioxin responsive element (DRE), also known as 
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a xenobiotic responsive element (XRE), in their promoter regions23. The collection of 
genes under the transcriptional control of AHR, known as the AHR gene battery, includes 
hundreds of genes and controls many physiological functions, including xenobiotic 
metabolism, immune system function, growth, and development24. 
1.3.3 Physiological roles of the AHR 
 The AHR, besides being a xenobiotic sensor protein, has multiple roles in normal 
physiological development. The AHR modulates expression of the estrogen receptor 1 
(ESR1), estrogen related receptor alpha (ESRRA) and estrogen related receptor gamma 
(ESRRG)24. Cytochrome P450 17A1 (CYP17A1) mRNA levels are affected by the AHR, 
catalyzing steps in the biosynthesis of steroid precursors24. Neuronal pentraxin I (Nptx1), 
also upregulated by AHR activation, is part of the neuronal stress pathway involved in 
apoptosis24.  
Untreated AHR knockout mice were shown to have compromised hepatic 
function and patent ductus venosus of the liver25, suggesting the need for a functional 
AHR in normal liver development. Activation of the AHR has been shown to affect 
human hematopoietic progenitor cell differentiation, with agonism leading to expansion 
of erythroid differentiation and antagonism leading to differentiation into 
megakaryocytes26. 
 Many studies suggest that the AHR plays a vital role in the regulation of the 
immune system. Commensal gut microbes are known to metabolize dietary tryptophan, 
creating kynurenines that activate the host’s AHR signaling pathway, ultimately 
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regulating immune response and gut homeostasis18. It has been suggested that the human 
AHR has adapted to ligands produced by native gut microbiota, providing an immune 
response that regulates host-microbe homeostasis, and exhibits a 2:1 binding 
stoichiometry to indole, which has not been seen with other AHR ligand-receptor 
pairings27. The AHR may also play a future role in the treatment in autoimmune diseases, 
as AHR activation by TCDD has ameliorated experimentally induced colitis in mice by 
upregulating regulatory T cells and down regulating T-helper 17 cells28. Interestingly, 
activation of AHR with an endogenous ligand, 6-Formylindolo[3,2-b]carbazole (FICZ), 
caused the upregulation of T-helper 17 cells, increasing imflammation28. 
1.3.4 Evolution of the AHR 
 The AHR is present in all Metazoan groups and has evolved independently in 
these diverse lineages. Mammalian AHRs are the most well studied and differences in 
species have been utilized to help characterize determinants of binding affinities to AHR 
agonists29. Non-mammalian vertebrate species exhibit a greater diversity of AHRs, with 
many species of fish containing more than one AHR gene – often expressed in different 
tissues and with varying affinities to DLCs30. 
Sharks and other cartilaginous fishes have four distinct AHR genes and can 
synthesize multiple aryl hydrocarbon receptor (AHR) isoforms30. Spiny dogfish shark 
(Squalus acanthias) AHR1 does not bind to typical dioxin-like ligands, however AHR2 
and AHR3 bind to dioxin-like chemicals and subsequently upregulate genes containing 
the dioxin responsive element (DRE) promoter region31. There is currently no binding 
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information available for the fourth spiny dogfish AHR isoform, AHR1X, which has high 
sequence homology to the mammalian AHR, suggesting it may be the ancestral ortholog 
to the human AHR31. 
1.3.5 Toxicological roles of the AHR 
 AHR ligands, especially synthetic and anthropogenic ligands, have been 
implicated in many situations where environmental and human health is at risk. One well-
known risk for human health is the AHR-dependent metabolism of benzo[a]pyrene 
(BaP), a carcinogenic byproduct of combustion that is found in smoke and charred foods. 
BaP is metabolized by cytochrome P450 1A1 (CYP1A1), part of the AHR gene battery. 
Metabolism of BaP forms an oxidized product, which can bind to and break DNA, 
damaging genetic information32. Other highly toxic AHR ligands, such as TCDD and 
PCBs, can cause developmental deformities, general dysbiosis, cancer, and even death in 
high enough doses33, but the mechanisms of DLC-mediated toxicity have not been fully 
elucidated. The AHRs of many species of vertebrates exhibit a highly variable sensitivity 
to DLCs, with some AHRs exhibiting no affinity for DLCs34. 
 For species with functional AHRs, differences in sensitivities are predictive of 
toxicity. Many studies have been completed in order to characterize the determinants of 
sensitivity35,36,37, which can include ligand-binding affinity as well as the gene targets of 
the activated AHR:ARNT transcription factor complex. In these studies, site-directed 
mutagenesis is often used in conjunction with homology modeling to locate amino acids 
of interest and mutate them to test their biochemical effects. 
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1.4 AHR Structure and modeling 
Protein function is determined by three-dimensional structure, which can be 
derived via direct experimental methods, such as x-ray crystallography, nuclear magnetic 
resonance (NMR), or cryo-electron microscopy. In some cases, protein structures cannot 
be experimentally derived, due to a variety of possible hinderances. In these cases, 
scientists can use computational methods to predict a protein’s structure in silico and 
create a three-dimensional model. These models allow researchers to accurately estimate 
the structure of a protein domain to guide experimental questions. 
Homologous protein sequences can be computationally modelled based on a 
known template structure. Usually, protein structures used as scaffolding to model other 
proteins share a relatively high percentage of amino acid identity because the proteins are 
evolutionarily related. 
Previous studies have shown that AHR homology models can be used to target 
amino-acid substitutions that may enhance binding in AHRs with low affinity to dioxin-
like compounds. The Danio rerio AHR1a does not bind TCDD, but binding was restored 
with Y296H and T386A (which correspond to mouse 285 and 375) mutations, although 
these mutants were not able to restore AHR gene battery activation38. A similar study 
investigated the Xenopus laevis AHR1β, which binds TCDD with low affinity. In the 
Xenopus study, the mutations N325S, A354S, and A370S (which correspond to mouse 
321, 359, and 375) all increased the AHR1β’s affinity to TCDD39. Both of these studies 
used the HIF2α structural template as the basis for their homology models and 
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demonstrate that homology modeling, in conjunction with site-directed mutagenesis, can 
be used to characterize binding determinants residing in the AHR’s ligand-binding 
domain. 
1.5 Squalus acanthias as a human model 
Elasmobranchs have long been used as vertebrate models because they are among 
the most primitive species exhibiting characteristics associated with human anatomy and 
physiology. These characteristics include the use of signaling molecules distributed via a 
closed circulatory system, molecular responses for salt/water homeostasis, and xenobiotic 
transport systems40. S. acanthias, also known as the spiny dogfish shark, is often used as 
a model elasmobranch due to its abundance and small size. It usually resides at depths of 
up to 3000 feet in cold water and may live up to 100 years. The cold temperatures of its 
habitat reduce the metabolic rate of this shark species and it also demonstrates resistance 
to normal hypoxic responses40. 
1.6 Hypotheses 
The aim of this study is to characterize key amino acid residues in the Squalus 
acanthias AHR1 (SaAHR1) ligand-binding domain LBD that may restore binding of 
SaAHR1 to dioxin-like chemicals. By characterizing binding determinants of the S. 
acanthias AHRs, we can better understand the differential binding affinities of AHR 
paralogs and orthologs and how this translates to sensitivity to toxic AHR agonists. In 
this study, I will test hypotheses about the functional significance of specific amino acid 
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residues in the LBD of SaAHR1 using homology modeling and experiments with 
heterologous expression system-reporter gene assays.  
Part of this study was a collaborative effort with the Bonati Laboratory. This 
involved making DNA constructs that code for point mutations to the SaAHR1 amino 
acid sequence recommended by the Bonati Laboratory’s structural homology modeling 
(based on the HIF2α structure). These SaAHR1 mutant constructs include 3 single 
mutants (R310C, L342M, and A359S) and 2 double mutants (R310C\A359S and 
L342M\A359S)A. 
During my analysis of the amino acid sequences, I discovered that the SaAHR1 
has a proline in position 380. The proline in this position is unique to SaAHR1 and does 
not appear in any other known isoform. Furthermore, this proline forms a diproline motif 
toward the C-terminal end of the LBD, which could greatly affect the secondary structure 
of this area considering proline’s rigidity regarding side chain rotation. An analysis of 
diproline segments in proteins has suggested that most diproline segments exist in only a 
few conformations and are affected by the amino acids flanking each side41. My 
hypothesis is that the diproline segment in SaAHR1 doesn’t allow for the rotational 
flexibility normally seen in AHR LBDs and therefore may restrict the overall structure 
and function of the protein. I will be creating duplicates of the aforementioned mutant 
constructs (from the Bonati laboratory’s recommendations), but also each with the P380L 
mutation (P380L, R310C\P380L, L342M\P380L, A359S\P380L, R310C\A359S\P380L, 
                                                             
A Corrada D and Bonati L. Department of Earth and Environmental Sciences, University 
of Milano-Bicocca. Milan, Italy. 
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and L342M\A359S\P380L), in order to test whether or not this novel diproline motif 
affects SaAHR1’s functional characteristics. 
After my analysis of the SaAHR1 primary structure, I determined that more 
information could be gathered by analyzing the tertiary structure and created my own 3D 
structural models of the SaAHR1. The models I’ve created are based on the human 
HIF1α structure, which is different than most AHR homology modeling studies that have 
been done in the past, including the Bonati collaboration. These models have helped to 
locate amino acid residues of interest for future studies. I have created a mutant SaAHR1 
construct to change one of these residues of interest (A375C). This specific residue has 
been implicated as a binding determinant in multiple studies of other AHR 
isoforms38,39,42. This alanine residue is part of a “faced-pair” of amino acid residues (359, 
375) that point inward toward the AHR ligand-binding cavity. 
If any of these specific amino acid residue changes in the LBD restore SaAHR1’s 
binding affinity to DLCs and subsequent activation, the presence or absence of such 
residues may be used to predict species at risk to the toxic effects mediated by activation 
of the AHR pathway.  
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2. Methods 
2.1 Homology Modeling 
 AHRs of multiple species were chosen for alignment based upon varying 
affinities for dioxin-like chemicals (Table 1). Alignments of the amino acid residues in 
the AHR ligand binding domains (LBDs) of multiple species were created using the 
ClustalW43 alignment tool in MacVector version 15.5.4 (Figure 2).  
 Three-dimensional structural models (.pdb format) of the AHR LBDs were 
created for a subset of the aligned isoforms (SaAHR1, 2, 3 and MmAHR) using 
MODELLER version 9.2144, 45 via the University of California San Francisco (UCSF) 
Chimera version 1.11.246. The basic local alignment search tool (BLAST)47 was used to 
query the Protein Data Bank (PDB)48 to find known protein structures that share the 
highest percentage amino acid identity. The search result with the highest percent 
homology was used as a structural template to model the AHR LBDs, in this case human 
hypoxia inducible factor 1α (HIF1α) (PDB ID: 4H6J_A49) and human HIF2α (PDB ID: 
1P9750) (Table 2). 10 output models were built for each AHR isoform with “build models 
with hydrogens” and “thorough optimization” options enabled. One representative model 
for each of the modeled ligand binding domains was chosen based upon their 
MODELLER-derived GA34151, where a value greater than 0.70 is correlated to a 95% 
probability that a model has the correct fold52, and zDOPE53 (normalized discrete 
optimized protein energy), where negative values are preferable scores52 (Appendix 1). A 
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qualitative analysis comparing both the amino acid alignments and the structural models 
was undertaken to identify residues of interest for site-directed mutagenesis. 
2.2 Mutagenic Primer Design 
 Specific amino acid changes (R310C, L342M, A359S, R310C\L342M, and 
L342M\A359S) were recommended by a computational analysis performed by the Bonati 
Laboratory. Other residues of interest (A375C and P380L) were identified via the 
computational analysis I performed. Mutagenic primers were designed using the 
QuikChange Primer Design online tool available from Agilent (Table 3). Polyacrylamide 
gel electrophoresis (PAGE) purified primers were ordered from Integrated DNA 
Technologies (IDT). 
2.3 Chemicals 
 3,3’,4,4’,5-Pentachlorobiphenyl (PCB 126) in dimethyl sulfoxide (DMSO), 2 
mg/ml, was obtained from AccuStandard, Inc (CAS# 57465-28-8, 99.5% purity). 
2.4 Cell Culture 
 Mammalian cell-cultures were maintained at 37°C with 5% supplemental CO2. 
COS7 cells (green monkey kidney epithelial cells, ATCC CRL-1651) were maintained in 
Dulbecco’s Modified Eagle’s Medium (DMEM, Sigma D7777), supplemented with 3.7 
g/L NaHCO3, with 10% fetal bovine serum (FBS) added. C35 cells (mouse liver 
hepatoma cells, derived from Hepa-1c1c7, ATCC CRL-2715) were maintained in alpha 
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minimum essential medium (αMEM, ATCC 30-2605), supplemented with L-glutamine 
(2mM final concentration), with 10% heat-inactivated FBS added. 
2.5 Expression Constructs  
 Full length Squalus acanthias AHR1 and AHR2 were cloned into DEST53 
expression vectors using the Gateway system prior to this project by the Merson 
Laboratory (Table 4). This DNA construct is expressed under the control of a 
cytomegalovirus (CMV) promoter and encodes an N-terminal eGFP-AHR fusion protein. 
An inducible firefly luciferase, pGudLuc 6.1, was a gift from M. Denison from 
University of California, Davis. A constitutive Renilla luciferase, pRL-TK, was included 
in the Promega Dual Luciferase Reporter Assay Kit. Full length Fundulus heteroclitus 
FhAHR2 and FhARNT2 were a gift from M. Hahn from Woods Hole Oceanographic 
Institution. A constitutive firefly luciferase, pGudLuc 4.13, was a gift from Promega 
technical support and was used to verify adequate transfection. 
2.6 SaAHR1 Site-Directed Mutagenesis 
 Site-directed mutagenesis was performed on the pDEST53SaAHR1 DNA 
construct previously created by the Merson Laboratory. Site-directed Mutagenesis was 
performed using a QuikChange Lightning Multi Site-Directed Mutagenesis Kit using an 
Eppendorf thermal cycler. The pDEST53SaAHR1 wildtype construct (50 ng), the 
mutagenic primer (100 ng), a dNTP mix (1 µl), the QuikChange Lightning Multi enzyme 
blend (1 µl), and the 10x QuikChange Lightning Multi reaction buffer (2.5 µl) was placed 
into a reaction tube in MilliQ water to a final volume of 25 µl. This mixture was cycled 
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(Table 5) and a proprietary DpnI restriction enzyme (10 units) was added afterward to 
digest the parental DNA strands. Digested DNA was transformed into ultracompetent 
XL-10 gold Escherichia coli, which were included in the kit, plated onto Luria broth 
(LB)-ampicillin (100 µg/ml) agar plates, and incubated overnight at 37 °C. Two colonies 
were chosen from each plate and grown in 5 ml LB-ampicillin (50 µg/ml) cultures 
overnight at 37°C with shaking at 250 rpm. Plasmid DNA was isolated from 5 ml 
cultures via QIAGEN Plasmid Mini Spin Kit (12125) using manufacturer’s protocols. 
Multiple mutant eGFP-SaAHR1 DNA constructs were created (Table 4) for future 
analysis. Each mutant construct was analyzed via DNA gel electrophoresis (0.8% 
agarose, 150V, 1 hour), and nanodrop spectroscopy. Specific mutations were confirmed 
via Sanger sequencing and subsequent analysis with MacVector version 15.5.4. 
2.7 Immunoblotting 
 To confirm that the expression constructs were active in the cell line, 
pDEST53SaAHR1 wildtype and mutant constructs (6 µg DNA/transfection) were 
transfected into COS7 cells in confluent T25 flasks using X-tremeGENE HP (6 
µl/transfection) transfection reagent. After 72 hours, cells were lysed using 700 µl 
Cellytic M (Sigma C2978) with cell-scraping necessary, and 10 µl protease inhibitor 
cocktail (Sigma P8340) was added. Lysates (10 µl/sample) were prepared with 2X 
protein loading dye (9.5 µl/sample), β-mercaptoethanol (0.5 µl/sample), and boiled for 5 
minutes. Lysate preparations (20 µl/well) were resolved via SDS-PAGE using BIO-RAD 
mini-PROTEAN Tetra apparatus with precast BIO-RAD Mini-PROTEAN TGX stain-
free gradient gels (4-15%). The resolved proteins were transferred onto a GE Amersham 
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Protran nitrocellulose membrane (0.45 µm pore size) using a BIO-RAD Trans-Blot semi-
dry transfer apparatus (15V, 0.9 hours). Western blotting, using rabbit anti-GFP-N-
terminal primary antibody (Sigma G1544, 1:500 concentration) and goat anti-rabbit 
horseradish peroxidase conjugated secondary antibody (Sigma A275, 1:10,000 
concentration), was performed to confirm eGFP-SaAHR1 fusion protein identity. The 
Western blot was visualized using BIORAD Clarity (170-5061) enhanced 
chemiluminescence reagents and a BIORAD ChemiDoc MP. 
2.8 Dual luciferase reporter gene assays  
 C35 cells were seeded in 48-well plates at 30,000 cells/well 24 hours prior to 
transfection (Figure 3). At the time of transfection, medium was refreshed using αMEM 
containing 10% heat-inactivated-FBS. pDEST53SaAHR1 wildtype or mutant constructs 
were co-transfected along with pGudLuc 6.1, pRL-TK, and FhARNT2 (Table 6, assay 6) 
using the lipofectamine 2000 (1 µl/well) transfection reagent in serum-free αMEM. We 
used the pDEST53SaAHR2 construct as an inducible positive control and pcDNA empty 
vector as a negative control. 24 hours post-transfection, 1.5 µl of either a DMSO only 
control or PCB 126 in DMSO (100 nM final concentration) was added to each well, using 
three replicate wells for each treatment group. A passive lysis buffer (100 µl) was added 
to each well and the lysates used for luciferase reporter gene AHR activation assays. A 
Turner Biosystems 20/20 luminometer and Promega Dual-Luciferase Reporter Assay 
System Kit was used to quantify luminescence in order to assess AHR activation (Figure 
4). The pGudLuc 4.13 plasmid was also used as a constitutively expressed positive 
control to confirm adequate transfection. 
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2.9 Epifluorescence Microscopy and AHR Localization Assays 
 Two 12-well glass bottom plates were seeded with COS7 cells (7.5 x 106 
cells/well, 24 hours prior to transfection). Medium was refreshed just prior to transfection 
with DMEM containing 10% FBS. Each well was transfected with pDEST53SaAHR1 
wildtype, mutants, or pDEST53SaAHR2 (1 µg DNA/well) using X-tremeGENE HP 
transfection reagent (3 µl/well) in serum-free DMEM. One 12-well glass bottom plate 
was used as a vehicle-only (2.5 µl DMSO/well) control, and one 12-well glass bottom 
plate was dosed with PCB 126 (2.5 µl of 20 µM PCB 126 in DMSO, for a final 
concentration of 50 nM). An Olympus IX81 microscope was used to visualize the eGFP-
SaAHR fusion proteins via epifluorescence on the FITC channel (excitation: 469-509 nm, 
emission: 488-528 nm). Images were taken with a Retiga camera using Q Imaging 
software 32 hours after dosing using the microscope’s 20X objective. 
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3. Results 
3.1 Homology models suggest residues of interest for SaAHR1 ligand binding 
 To determine amino acid residues that differ among various isoforms of AHR 
with differential binding affinities, a ClustalW alignment of ligand binding domains 
(residues 278-385) was generated. This alignment revealed distinct amino acid residues 
of interest for further analysis (Figure 2). The residue P380 is of great interest in the 
SaAHR1, because it is not known to be present in any other AHR isoforms. This residue 
creates a novel diproline motif toward the C-terminal side of the LBD, which could 
restrict the overall structure, and therefore affect the function, of the SaAHR1.  
BLAST results of  LBDs selected for 3D structural modelling (SaAHR1, 
SaAHR2, SaAHR3, and MmAHR) show that the proteins with known structure and the 
highest percent homology are human hypoxia inducible factor 1α (HIF1α, PDB ID: 
4H6J_A49) and human hypoxia inducible factor 2α (HIF2α. PDB ID: 1P9750) (Table 2). 
The two sets of structural models created from these scaffolds allowed for further 
scrutinization of residues of interest, such as their 3D location, and the possible relation 
of each residue’s sidechain to the ligand binding cavity (Figures 5-8, 14). In the analysis 
that follows, I have adopted the secondary structure nomenclature used in other AHR 
LBD studies39,54 (Figure 5). 
My analysis of these two modeling scaffolds reveals overall agreement in much of 
the modelled ligand binding domain. There are some basic secondary structure 
differences in the models. The HIF1α-based models (Figure 6) split both the Gβ and Hβ 
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strands into two separate strands each, which I will refer to as Gβ1, Gβ2, Hβ1, and Hβ2 
(Figure 5). The HIF2α-based models maintain a closer structural resemblance to the 
HIF2α template (Figure 6). Another notable difference between HIF1α and HIF2α based 
models is the length of the β-strand on the C-terminal end of the LBD, Iβ. All of the 
models generated based upon HIF1α terminate the Iβ-strand around residue 375, bending 
the Iβ-strand away from the interior of the ligand binding cavity, disagreeing with the 
original HIF1α template The models based on HIF2α more closely resemble the Iβ-strand 
in the HIF2α template. The exception to the larger Iβ-strand in the HIF2α-based models 
is the SaAHR1 WT. This model bends the Iβ-strand away from the ligand binding cavity 
around residue 375, similar to the HIF1α models (Appendix 2). 
The mutations recommended by the Bonati Laboratory were visualized in the 
HIF1α-based models, comparing the residue side chains between SaAHR1 and SaAHR2 
(Figure 8 A-C). For each of the three mutations (R310C, L342M, and A359S) the 
SaAHR1 residue was mutated to its analogous residue in the SaAHR2. The mutation 
R310C (Figure 8A) is pointed away from the ligand-binding cavity in the flexible belt 
portion of the AHR LBD. The mutations L342M and A359S (Figures 8B, 8C) are located 
on the internal side of the β-sheet that creates the ligand-binding cavity. 
According to my analysis of the 3D models, the SaAHR1 residue A375 (Figure 
8D) is of interest due to its side chain chemistry, location, and importance in previous 
studies of other AHR isoforms. It is centrally located, pointing inward toward the ligand 
binding cavity. This residue is a cysteine in the SaAHR2 isoform, which readily binds to 
DLCs, and the cysteine’s sidechain chemistry may restore binding affinity to the 
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SaAHR1 A375C mutant construct (which was created during this study but not yet 
tested). 
3.2 SaAHR1 mutant constructs contain verified mutations and express protein in COS7 
cells. 
 In order to verify the presence and size for each DNA mutagenesis construct 
plasmid preparation, each construct was resolved via gel electrophoresis (Figure 9). This 
DNA gel shows the presence of each mutant plasmid isolated from an individual plated 
colony, and the size of each mutant plasmid is consistent with the wildtype 
pDEST53SaAHR1 (8935 bp). To verify successful introduction of specific mutations, 
each mutant construct (except A375C) was analyzed via Sanger sequencing and did 
contain their respective mutations (Figure 10). Western blotting of a subset of mutants 
suggests that the mutant protein is expressed and is consistent in size with the wildtype 
pDEST53SaAHR1 eGFP fusion protein (calculated at 131.5 kDa) (Figure 11). 
3.3 Reversion of the SaAHR1 diproline motif with the P380L mutation does not restore 
inducible activation with PCB 126. 
To determine whether the diproline motif impaired DLC binding and SaAHR1 
activation, a dual luciferase reporter gene assay was conducted. There was no difference 
in activation of the reporter in SaAHR1 WT (with diproline present) and SaAHR1 P380L 
(with diproline reverted) (Figure 12), suggesting that the diproline alone was not 
implicated in the nonbinding character and lack of transactivation activity. This 
experiment was performed with FhARNT2 co-transfected to determine if ARNT was a 
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limiting factor in previous experiments (Appendix 3), with similar results reported both 
with and without ARNT. 
 Luciferase assays were also used to assess activation of the pDEST53SaAHR1 
double mutants R310C/A359S and L342M/A359S (Appendix 4). These results were not 
included here due to low raw luminescence readings, possibly due to low transfection 
efficiency of the luciferase-encoding plasmids (Appendix 5).  
3.4 Epifluorescence microscopy shows a unique localization of SaAHR1 WT and mutants. 
To determine the localization of the SaAHR1 protein in the heterologous 
expression system, transfected cells were visualized via N-terminal eGFP-SaAHR fusion 
protein and imaged (Figure 13). The images show some portion of the GFP-tagged 
protein, representing SaAHR1 WT, SaAHR1 mutants, and SaAHR2, is translocated to 
the nucleus in the COS7 cells, even in vehicle-only control wells. This is unexpected due 
to the mechanism of AHR activation, normally translocating to the nucleus only after 
agonist-binding. The P380L mutant seemed to exhibit the lowest amount of nuclear 
localization of any of the tested constructs. 
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4. Discussion 
 The models produced with the MODELLER function of the UCSF Chimera 
program produced interesting results. One notable difference between using human 
HIF1α as a template and using human HIF2α as a template is the size of the modelled 
ligand binding cavity. In the HIF1α based models, the overall size of the ligand binding 
cavity seems greatly reduced compared to the HIF2α models. This is in part due to the 
length of the β-strand on the C-terminal end of the LBD, Iβ. The HIF1α-based models all 
terminate the Iβ-strand around residue 375, presumably due to the lack of homologous 
residues past that point (Appendix 8). These models all bend the Iβ-strand away from the 
interior of the ligand binding cavity, creating a much smaller antiparallel β-sheet and thus 
a smaller surface area for binding to occur.  
The HIF2α template allows for the SaAHR2 and SaAHR3 models to more closely 
conform to the Iβ-strand in the HIF2α structure due to a homologous leucine 380 residue. 
Interestingly, this is the same position that creates the diproline motif in the SaAHR1 
isoform. Presumably, this lack of the homologous leucine 380 residue causes the 
SaAHR1 HIF2α-based model to more closely resemble the HIF1α-based models, bending 
the Iβ-strand away from the ligand binding cavity (Appendix 2). Usually, β-strands in 
antiparallel β-sheets will have a primary amino acid structure that alternates amino acid 
side chain character between hydrophobic and hydrophilic5. The homology modelling 
programs could more closely rely on homology alone, forcing models to conform to the 
known structure rather than using the actual side chain biochemical properties to 
determine secondary and tertiary structure formation. If the real structure of some AHRs 
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more closely resemble that of HIF1α, the HIF2α homology models could be greatly 
overestimating the size of the β-sheet that makes up a large portion of the ligand binding 
cavity.  
 Both HIF1α-based and HIF2α-based structural models have a similar “flexible 
belt area”, which was previously theorized to be critical for ligand binding54. The amino 
acid residues that Xing, et al. hypothesized to be critical to ligand binding in MmAHR 
(F318 and I319) are conserved in all SaAHR isoforms. The same study also found that 
G315 is critical for MmAHR belt flexibility, and this residue is also conserved in all 
SaAHR isoforms. If the flexible belt area is well conserved in most AHR isoforms, and is 
critical for ligand binding, then the area opposite the flexible belt (the β-sheet) could 
cause the differences in binding affinities that we see in some AHR isoforms. This 
concept has been tested in many studies, and multiple residues in the interior-facing 
portion of the β-sheet have been mutated and resulted in a higher binding affinity to 
DLCs38,39,42. 
 Some of the studies that have increased binding affinity with certain mutations to 
residues in the β-sheet share these homologous residues in the SaAHR1 LBD. In birds, 
the AHR1 has been suggested to have a faced residue pairing of great importance (359 
and 375)42. When one of these residues is alanine and the opposite is serine, the AHR will 
have a higher binding affinity than if both were alanine. In Xenopus laevis, AHR1β was 
mutated to increase its affinity for TCDD using mutations analogous to A359S and 
A375S39.  
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The residues on the interior portion of the ligand binding cavity could be 
interacting to form a charged surface. The HIF1α models of the SaAHRs bend the Iβ-
strand away from the interior of the ligand-binding cavity around residue 375. In 
SaAHR2, which binds to DLCs, the cysteine 375 residue in that location pulls away from 
the interior cavity further than the alanine 375 in the SaAHR1 model. If these models are 
accurate, the Iβ-strand could be key to understanding the variable ligand binding 
properties of the SaAHRs. If this Iβ-strand is part of a hinge that imparts some amount of 
flexibility into the SaAHRs, it could “close” upon ligand binding, thus enlarging the 
antiparallel β-sheet and providing a more sterically favored area for dimerization with 
ARNT.  
Residue 375 is also adjacent to other residues of interest, 342 and 359, and 
together these residues could create a localized area that is more favorable for binding 
DLCs. This may be a good example of how multiple residues interact to form a charged 
surface in a ligand binding cavity (Figure 14). I’ve created a pDEST53SaAHR1 construct 
with the mutation A375C for future study to test the effect of this residue’s chemistry on 
the binding ability of the SaAHR1’s LBD. 
 The luciferase reporter gene assays testing the SaAHR1 P380L mutant suggests 
no difference in activation when compared to SaAHR1 WT (Figure 12). This experiment 
was previously performed without cotransfection of a Fundulus heteroclitus ARNT2 
construct. The addition of FhARNT2 in assay 6 (Figure 12) was to determine if ARNT 
was a limiting factor in the C35 cell line used for these experiments. The results were 
similar with and without ARNT cotransfection (Appendix 3), so it is reasonable to infer 
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that ARNT cotransfection is not required for AHR-based luciferase assays while using 
the C35 cell line. It is important to note that this assay only correlates to AHR activation 
and does not assess binding affinity. This means that the mutation in question may or 
may not increase binding affinity to PCB 126, but the results are not determinative of this 
question.  
 Luciferase reporter gene assays assessing activation of the SaAHR1 double 
mutants R310C/A359S and L342M/A359S were also conducted (Appendix 4). These 
results were not included in this paper due to very low raw luminescence readings for 
both the induced firefly luciferase as well as the constitutive Renilla luciferase (Appendix 
5). This could be due to low transfection efficiency of the luciferase encoding plasmids in 
these experiments. Because some of the luciferase assay experiments seemed unreliable, 
we switched from expression in the C35 cell line to expression in the COS7 cell line. 
Epifluorescence microscopy experiments and western blotting were utilized to confirm 
adequate expression of the pDEST53SaAHR constructs in the COS7 cell line. 
 Interestingly and quite unexpectedly, the pDEST53 eGFP-SaAHR1 fusion 
proteins (wildtype and mutants) are localized in the nucleus when visualized via 
epifluorescence microscopy (Figure 13). This localization occurred in both PCB 126 
dosed wells and vehicle-only control wells for most of the pDEST53 eGFP-SaAHR1 
fusion proteins, with the exception of the SaAHR1 P380L mutant (Figure 13). The P380L 
mutation may have changed the shape of the protein enough to retain it in the cytoplasm, 
or this result could simply be due to low transfection efficiency. Most characterized AHR 
isoforms exhibit cytoplasmic localization and only translocate to the nucleus upon 
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binding with an agonist. The aberrant localization seen in the epifluorescence microscopy 
images may be due to the proximity of the eGFP to the AHR’s N-terminal nuclear 
localization sequence. In order to test this, the C-terminal SaAHR1-eGFP fusion protein 
(which was already created in the Merson Lab, pDEST47SaAHR1) should be tested 
alongside the pDEST53SaAHR1 construct in a nuclear localization assay. If the C-
terminal SaAHR1-eGFP fusion protein revealed similar results to the N-terminal eGFP-
SaAHR1 fusion protein, this abnormal localization could be due to the SaAHR1 evolving 
a different function than most vertebrate AHRs. Another experiment that may change this 
localization would involve co-transfecting AHR chaperones, such as ARA9, in order to 
preserve the three-dimensional fold of SaAHR1, which may keep the NLS hidden from 
cellular machinery prior to ligand-binding. Another possibility regarding the localization 
of the eGFP-AHR fusion proteins could involve unknown endogenous ligands being 
present in the medium or in the COS7 cell line. 
There are many ways to further probe the structure/function characteristics of 
SaAHR1. One such way would be to create a chimeric protein substituting domains of 
the DLC-binding SaAHR proteins, perhaps first concentrating on a chimeric SaAHR1 
with an SaAHR2 LBD and a chimeric SaAHR1 with a SaAHR2 transactivation domain 
(TAD). This would allow us to determine whether SaAHR1 can be a functioning 
transcription factor even if the LBD is changed to the point of restoring agonist binding. 
Other labs have deleted the entire LBD of mouse AHR, which prevents binding to the 
chaperone HSP90, and ultimately causes “a ligand-independent constitutively active 
AHR”55. 
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 If it is determined that the SaAHR1 chimera containing the SaAHR2 LBD does 
not activate DREs, it would be interesting to test the library of mutant constructs created 
during the course of this study in ligand-binding assays. This would allow the binding 
affinities to be measured independent of any activation-induced gene transcription events. 
Ultimately, we may find that the SaAHR1 has evolved a different function than other 
AHRs, but further experimentation will be needed to make this determination. 
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Figure 1: AHR is a ligand-activated transcription factor. (1) AHR binds agonist, (2) AHR 
translocates into nucleus, (3) ARNT dimerizes with AHR, (4) AHR:ARNT transcription factor 
complex binds to DREs on DNA, (5) genes under control of DREs are transcribed. 
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Figure 2: Amino acid alignment of AHR LBDs. Numbering conforms to full length 
mouse AHR amino acid sequence. Triangles denote mutations recommended by the 
Bonati Laboratory (R310C, L342M, and A359S) and arrows denote mutations 
determined by my analysis of homology models (A375C and P380L). Species 
abbreviations available in Table 1. Modelled area and secondary structures of models 
noted. 
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Table 5: Thermal cycling parameters
Segment Cycles Temp. (°C) Time (minutes)
Denaturation 1 95 2:00
Denaturation 30 95 0:20
Annealing 55 0:30
Extension 65 4:30
Final Extension 1 65 5:00
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Figure 3: Experimental design for luciferase reporter gene assays. C35 cells were 
seeded into 48-well plates at 30,000 cells/well. At 24 hrs post-plating, medium was 
refreshed and DNA constructs co-transfected with Lipofectamine 2000. At 48 hrs post-
plating, cells were dosed with either PCB-126 in DMSO (100 nM final concentration) or 
vehicle-only control. At 72 hrs post-plating, cells were lysed and lysates used for dual 
luciferase reporter gene assays. 
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Table 6: Luciferase assays performed during the course of this study.
Assay Date Cell type Transfected plasmids DNA (ng/well) Transfection reagent Objective of experiment
1 2/19/2015 C35 pDEST53Sa2 50 Turbofect
pDEST53Sa1 WT 50
pDEST53Sa1 R310C/A359S 50
pDEST53Sa1 L342M/A359S 50
pGudLuc 6.1 20 Results shown in Appendix 4, 5
pRL-TK 3
pcDNA empty vector 50
2 3/16/2015 C35 pDEST53Sa2 15 Lipofectamine 2000
pDEST53Sa1 WT 50
pDEST53Sa1 R310C/A359S 50
pDEST53Sa1 L342M/A359S 50
pGudLuc 6.1 20 Results shown in Appendix 4, 5
pRL-TK 3
pcDNA empty vector 50
3 4/10/2015 C35 pDEST53Sa2 15 Lipofectamine 2000
pDEST53Sa2 30
pGudLuc 6.1 20
pRL-TK 3 Results shown in Appendix 6, 9
4 4/23/2015 C35 pDEST53Sa2 15 Lipofectamine 2000
pDEST53Sa2 30
pGudLuc 6.1 20
pRL-TK 3 Results shown in Appendix 6, 9
5 7/7/2015 C35 pDEST53 Sa2 15 Lipofectamine 2000
pDEST53 Sa1 WT 50
pDEST53 Sa1 P380L 50
pGudLuc 4.13 50
pGudLuc 6.1 20 Results shown in Appendix 3, 7
pRL-TK 3
pcDNA EV 50
6 7/16/2015 C35 pDEST53Sa2 15 Lipofectamine 2000
pDEST53Sa1 WT 50
pDEST53Sa1 P380L 50
FhAHR2 20
FhARNT2 50
pGudLuc 4.13 50 Results shown in Figure 12, Appendix 7
pGudLuc 6.1 20
pRL-TK 3
pcDNA EV 50
Assessment of AHR1 with diproline segment 
reverted to P-L.
Assessment of AHR1 with diproline segment 
reverted to P-L, with FhARNT2 added to all 
wells.
Assessment of AHR1 double mutants 
(R310C/A359S, L342M/A359S).
Assessment of AHR1 double mutants 
(R310C/A359S, L342M/A359S).
Optimization of experimental timeline: Dosing 6 
or 24 hours post-transfection.
Optimization of experimental timeline: Dosing 6 
or 24 hours post-transfection.
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Figure 4: Luciferase reporter gene assay of AHR activation. (1) Activated AHR:ARNT 
transcription factor complex aids in expression of firefly luciferase, (2) luciferin substrate 
added to lysates, (3) luciferase catalyzes reaction on substrate, which produces luminescence. 
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  Figure 5: A HIF1α-based 3D model of the SaAHR2 LBD complexed with TCDD. 
Nomenclature of secondary structure is overlaid. Residues 279-377. 
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Figure 6: A cluster of HIF1α-based AHR models. 10 Models for each MmAHR WT 
(gray), SaAHR1 WT (red), and SaAHR2 WT (blue). Residues 279-377. 
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    Figure 7: A cluster of HIF2α-based AHR models. 10 Models for each MmAHR WT (light 
blue), SaAHR1 WT (magenta), and SaAHR2 WT (dark green). Residues 278-385. (Ribbon 
positions 379-385 hidden in SaAHR1 for ease of viewing. 
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Figure 8: HIF1α-based structural models of SaAHR1 (red) and SaAHR2a 
(blue): Molecular structure of residues of interest shown (A) R310C, (B) L342M, 
(C) A359S, (D)A375C. 
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Figure 9: DNA gel electrophoresis of pDEST53SaAHR1 WT and mutant constructs. 
Mutant constructs are present and consistent in size with wildtype. 
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Figure 10: Chromatograms of Sanger sequencing reads show the presence of specified 
mutations in each mutant DNA construct, with the exception of A375C (no data 
available). 
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Figure 11: Western blot of pDEST53SaAHR1 WT and mutant constructs show 
expressed protein with a size consistent with pDEST53SaAHR1 WT calculated size 
(131.5 kDa). Blotting performed using rabbit anti-GFP-N-terminal primary antibody. 
Dotted line represents area of blot that was removed in image editing software. 
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Figure 12: Luciferase assay 6, the P380L mutation did not cause PCB 126 induced 
activation in dual luciferase reporter gene assay. SaAHR2 was used as a positive control 
and a pcDNA empty vector was used as a negative control. All replicates were cotransfected 
with FhARNT2. Bars denote mean value of triplicate wells, error bars denote 1 standard 
deviation. PCB 126 final concentration of 100 nM. Asterisk denotes values significantly 
different (P<0.01) from DMSO only control, Student’s t test.  
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Figure 13: Epifluorescence microscopy (20X objective) of eGFP-AHR-transfected 
COS7 cellular localization assay. Images were taken 30 hours post dosing (50 nM final 
concentration) with either PCB-126 in DMSO or vehicle only. White triangles denote 
possible nuclear localization. Scale bar in top left image measures 50 µm. 
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Figure 14: Residues 342, 359, and 375 are adjacent and could form a charged 
surface for ligand binding. (A) HIF1α-based models, (B) HIF2α-based models. Ribbon 
positions 284-291 hidden for ease of viewing. 
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Isoform Model GA341 zDOPE Model GA341 zDOPE
1 0.81 -0.07 1 0.93 -0.41
2 0.70 0.00 2 0.88 -0.64
3 0.59 -0.04 3 0.82 -0.47
4 0.85 0.04 4 0.87 -0.39
MmAHR 5 0.87 -0.03 5 0.92 -0.39
6 0.87 0.01 6 0.81 -0.48
7 0.63 -0.02 7 0.83 -0.57
8 0.91 -0.10 8 0.82 -0.41
9 0.62 0.04 9 0.86 -0.65
10 0.74 0.06 10 0.82 -0.32
1 0.93 -0.21 1 0.92 -0.03
2 0.93 -0.23 2 0.77 0.08
3 0.76 -0.45 3 0.88 -0.17
4 0.89 -0.10 4 0.91 -0.10
SaAHR1 5 0.83 -0.40 5 0.99 0.05
6 0.90 -0.37 6 0.85 -0.12
7 0.96 -0.37 7 0.79 -0.07
8 0.94 -0.18 8 0.91 -0.23
9 0.86 -0.01 9 0.73 -0.19
10 0.94 -0.18 10 0.90 -0.17
1 0.96 -0.34
2 0.99 -0.56
3 0.85 -0.39
4 0.80 -0.50
SaAHR1 5 0.89 -0.45
P380L 6 0.96 -0.53
7 0.95 -0.46
8 0.86 -0.36
9 0.83 -0.33
10 0.93 -0.48
1 0.54 -0.15 1 0.93 -0.31
2 0.50 -0.02 2 0.82 -0.25
3 0.55 -0.06 3 0.58 -0.34
4 0.82 -0.02 4 0.81 -0.29
SaAHR2 5 0.57 -0.12 5 0.79 -0.34
6 0.58 0.00 6 0.91 -0.52
7 0.54 -0.04 7 0.72 -0.48
8 0.35 -0.13 8 0.75 -0.26
9 0.79 -0.06 9 0.83 -0.43
10 0.80 0.03 10 0.74 -0.45
1 0.85 0.14 1 0.98 -0.19
2 0.67 0.09 2 0.77 -0.42
3 0.73 0.14 3 0.92 -0.37
4 0.71 0.16 4 0.84 -0.41
SaAHR3 5 0.84 0.17 5 0.93 -0.32
6 0.65 0.12 6 0.88 -0.44
7 0.84 -0.08 7 0.91 -0.14
8 0.77 0.17 8 0.95 -0.25
9 0.74 0.07 9 0.90 -0.39
10 0.58 0.08 10 0.86 -0.31
HIF1α-based HIF2α-based
Mutation is outside of 
modelled area
Models not created.
Appendix 1: Raw scores from Modeller results. Bold font denotes 
one representative model from each isoform.
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Appendix 2: Representative models of HIF2α-based SaAHR1 WT and SaAHR2 
WT. Strand Iβ pulls away from the β-sheet earlier in the SaAHR1 WT model due to 
the presence of the diproline motif. 
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Appendix 3: Luciferase assay 5, the P380L mutation did not cause PCB 126 induced 
activation in dual luciferase reporter gene assay. SaAHR2 was used as a positive control 
and a pcDNA empty vector was used as a negative control. This experiment did not include 
FhARNT2 cotransfection. Bars denote mean value of triplicate wells, error bars denote 1 
standard deviation. PCB 126 final concentration of 100 nM. Asterisk denotes value 
significantly different (P<0.02) from DMSO only control, Student’s t test.  
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Appendix 4: Luciferase assays 1(A) and 2(B), the L342M/A359S and R310C/A359S 
double mutants did not cause PCB 126 induced activation in dual luciferase reporter 
gene assay. These results were not included in the body of this work due to low and 
possibly unreliable raw luminescence values. SaAHR2 was used as a positive control and a 
pcDNA empty vector was used as a negative control. This experiment did not include 
FhARNT2 cotransfection. Bars denote mean value of triplicate wells, error bars denote 1 
standard deviation. PCB 126 final concentration of 100 nM.  
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firefly Renilla RLU firefly Renilla RLU
457 370 1.2344 158 279 0.5667
DMSO 365 247 1.476 DMSO 208 683 0.3051
Sa2 214 239 0.8954 Sa2 7201 2261 3.1846
810 401 2.0175 12162 5918 2.055
PCB 126 253 297 0.8524 PCB 126 20632 5815 3.5478
151 201 0.7504 19630 4980 3.9418
124 218 0.5688 210 350 0.6006
Sa1 DMSO 120 275 0.4387 Sa1 DMSO 187 295 0.6337
L342M 135 204 0.661 L342M 458 1511 0.3036
+ 128 202 0.6333 + 486 1636 0.2975
A359S PCB 126 128 196 0.6531 A359S PCB 126 604 1703 0.3548
117 215 0.5426 746 1756 0.425
118 218 0.5447 235 1167 0.2018
Sa1 DMSO 132 197 0.6726 Sa1 DMSO 146 238 0.6144
R310C 135 229 0.5877 R310C 567 1798 0.3157
+ 188 243 0.772 + 430 2102 0.2048
A359S PCB 126 121 202 0.5971 A359S PCB 126 366 1784 0.2054
121 227 0.5347 606 2305 0.2633
206 404 0.5121 1196 4306 0.2778
DMSO 244 315 0.776 DMSO 170 372 0.4574
Sa1 147 251 0.586 Sa1 1553 3809 0.4078
WT 150 251 0.5971 WT 1771 5188 0.3414
PCB 126 279 393 0.7102 PCB 126 1494 5116 0.2921
208 444 0.4697 1504 3913 0.3845
143 302 0.4742 1245 2289 0.544
DMSO 150 222 0.6746 DMSO 846 1650 0.513
pcDNA 143 222 0.6454 pcDNA 1986 3934 0.5049
EV 149 245 0.6077 EV 5149 9306 0.5533
PCB 126 145 252 0.577 PCB 126 5003 11559 0.4328
135 216 0.6244 Third replicate value lost
Appendix 5: Luciferase assay luminescense raw values for assays 1 and 2
Assay 2Assay 1
61 
 
  
firefly Renilla RLU firefly Renilla RLU
281 1044 0.2692 7400 6300 1.1746
Sa2 DMSO 4042 846 4.7752 Sa2 DMSO 6205 5907 1.0505
6 hours 278 507 0.549 6 hours 5224 5720 0.9133
15 ng DNA 131 278 0.4729 15 ng DNA 44086 4340 10.1564
PCB 126 508 765 0.6641 PCB 126 22721 3678 6.1763
279 742 0.3772 1222 1820 0.6713
321 539 0.5968 35049 12989 2.6983
Sa2 DMSO 420 697 0.6038 Sa2 DMSO 30433 12198 2.4948
6 hours 141 474 0.298 6 hours 36829 12742 2.8903
30 ng DNA 477 484 0.9864 30 ng DNA 181076 15031 12.0465
PCB 126 553 606 0.9115 PCB 126 181953 15954 11.4045
1400 1054 1.3274 200447 13849 14.4729
16335 7315 2.2331 3561 2275 1.5653
Sa2 DMSO 12957 9244 1.4017 Sa2 DMSO 58316 4739 12.3055
24 hours 9675 8499 1.1384 24 hours 14684 4581 3.2052
15 ng DNA 12247 7046 1.7382 15 ng DNA 15597 2476 6.2977
PCB 126 16965 8442 2.0096 PCB 126 65985 5706 11.5629
14245 5127 2.7783 11068 1251 8.8413
23989 8943 2.6824 59953 11916 5.031
Sa2 DMSO 25186 7757 3.2467 Sa2 DMSO 46801 9836 4.758
24 hours 953 1288 0.7401 24 hours 84294 7779 10.8358
30 ng DNA 6440 3084 2.0881 30 ng DNA 323273 13075 24.7239
PCB 126 15128 8673 1.7442 PCB 126 240893 12530 19.2245
28943 9165 3.1578 266409 12291 21.6751
Assay 3 Assay 4
Appendix 6: Luciferase assay luminescense raw values for assays 3 and 4
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firefly Renilla RLU firefly Renilla RLU
31977 38250 0.836 88867 53236 1.6693
DMSO 26390 38649 0.6828 DMSO 115113 72995 1.577
Sa2 21382 28717 0.7446 Sa2 79749 60513 1.3179
14526 13600 1.0681 319767 81464 3.9253
PCB 126 50330 28828 1.7459 PCB 126 186850 54938 3.4011
53635 34505 1.5544 127319 42526 2.9939
3828 22756 0.1683 24639 34114 0.7223
DMSO 4947 24028 0.2059 DMSO 23895 31904 0.749
Sa1 3625 22173 0.1635 Sa1 29158 39675 0.7349
P380L 2926 12654 0.2312 P380L 32087 41349 0.776
PCB 126 5476 21379 0.2562 PCB 126 28402 33430 0.8496
4902 26665 0.1839 24144 32078 0.7527
7691 33814 0.2275 36203 45395 0.7975
DMSO 6533 31008 0.2107 DMSO 37184 46222 0.8045
Sa1 7947 35288 0.2252 Sa1 46174 52258 0.8836
WT 8633 21419 0.4031 WT 46953 57553 0.8158
PCB 126 6001 28363 0.2116 PCB 126 39106 39387 0.9929
6308 29765 0.2119 30432 33496 0.9085
20560674 13136 1565 153667024 58237 2638
DMSO 35686976 23896 1493 DMSO 148657344 52085 2854
pGL 36266048 20220 1793 pGL 165592592 64682 2560
4.13 5195250 6845 758.901 4.13 170774336 65619 2602
PCB 126 34280424 20845 1644 PCB 126 162415440 59972 2708
33775972 21542 1567 144758880 53262 2717
17949 80147 0.224 120165 102773 1.1692
DMSO 15827 61235 0.2585 DMSO 81386 71168 1.1436
pcDNA 19092 70299 0.2716 pcDNA 111004 93026 1.1933
EV 10055 46166 0.2178 EV 140270 116439 1.2047
PCB 126 15803 66438 0.2379 PCB 126 74448 73613 1.0113
15958 67104 0.2378 83627 67479 1.2393
295 341 0.8672 2017297 54276 37.167
COS7 DMSO 772 361 2.1364 DMSO 2530627 62795 40.2992
untransfected 381 341 1.1188 FhAHR2 3068355 88995 34.4776
control 203 343 0.593 3333815 66278 50.2999
PCB 126 207 351 0.5908 PCB 126 4563634 72341 63.0842
189 335 0.5652 4105533 68834 59.6439
Assay 6Assay 5
Appendix 7: Luciferase assay luminescense raw values for assays 5 and 6
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Appendix 8: Alignments of structural templates (HIF1α and HIF2α) vs. model sequence 
(SaAHR1 and SaAHR2). Screenshots taken from UCSF Chimera program. Green 
highlighted sequence denotes β-strand in structural template. Yellow highlighted sequence 
denotes α-helix in structural template. AHR sequences start at residue 278. Conservation 
symbols: asterisk denotes homologous residue, colon denotes highly similar residue, period 
denotes less similar residue. (A) HIF1α vs. HIF2α, (B) HIF1α vs. SaAHR1 and SaAHR2, (C) 
HIF2α vs. SaAHR1 and SaAHR2. 
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Appendix 9: Luciferase assays 3(A) and 4(B), optimization of SaAHR2 transfection 
amount (15 ng vs. 30 ng) and dosing timepoint (6 hr vs. 24 hr post transfection). This 
experiment did not include FhARNT2 cotransfection. Bars denote mean value of triplicate 
wells, error bars denote 1 standard deviation. PCB 126 final concentration of 100 nM. 
Asterisks denote values significantly different from DMSO only control, Student’s t test (* 
=P<0.02, ** =P<0.005). 
